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Abstract: Immunocompromised patients are traveling at increasing rates. Physicians caring 
for these complex patients must be knowledgeable in pretravel consultation and recognize when 
referral to an infectious disease specialist is warranted. This article outlines disease prevention 
associated with international travel for adults with human immunodeficiency virus, asplenia, 
solid organ and hematopoietic transplantation, and other immunosuppressed states. While rates 
of infection may not differ significantly between healthy and immunocompromised travelers, 
the latter are at greater risk for severe disease. A thorough assessment of these risks can ensure 
safe and healthy travel. The travel practitioners’ goal should be to provide comprehensive 
risk information and recommend appropriate vaccinations or prevention measures tailored to 
each patient’s condition. In some instances, live vaccines and prophylactic medications may 
be contraindicated.
Keywords: immunocompromised, vaccines, travel, malaria, diarrhea
Introduction
International travel continues to grow at an astonishing rate, with more than one billion 
tourist arrivals reported globally in 2013.1 Travel to a wide range of destinations has 
become easier and more attainable for an increasingly diverse population of global 
travelers. Immunocompromised travelers include those with primary immunodefi-
ciencies, malignancy, or human immunodeficiency virus (HIV) infection and others 
receiving iatrogenic immunosuppression for organ transplantation, rheumatologic 
disorders, and autoimmune diseases. Studies estimate that anywhere from 16% to 
48% of solid organ transplant (SOT) recipients have traveled to tropical regions and 
other areas where the risk of acquiring infectious diseases may be elevated.2 While 
rates of infection are not higher in immunosuppressed travelers, severity of illness 
can be markedly increased.3–5
Severely immunocompromised travelers should seek consultation with an infec-
tious diseases specialist whenever possible. Primary care physicians, rheumatologists, 
and transplant specialists must likewise be equipped to provide advice to this unique 
population of travelers, both pre- and postdeparture. In a study of 267 transplant 
recipients, 36% traveled outside the US and Canada and 66% sought pretravel care by 
their transplant physicians. Despite pretravel consultation, only 5% of those traveling 
to a hepatitis A endemic region received the hepatitis A vaccine.4 Improved pretravel 
consultation can prevent potentially devastating infections. This review provides 
guidance on infectious disease prevention for clinicians charged with counseling and 
caring for immunocompromised travelers.
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Consultation for immunocompromised patients should begin 
several months ahead of departure in order to assess and miti-
gate risks associated with travel. A structured approach that 
accounts for each patient’s unique immunocompromised state 
improves pretravel guidance and interventions (Table 1).
Depending on their destination, travelers can be at height-
ened risk of exposure to endemic infectious diseases, many 
of which may be vector borne. Detailed country-specific – 
and even city-specific – information regarding existing 
infectious disease threats can be found in routinely updated 
resources provided by the Centers for Disease Control and 
Prevention (CDC).5 Specific interventions to counter these 
threats, including immunizations and chemoprophylaxis, 
should hinge upon the likelihood that a traveler may come 
in contact with these diseases and their vectors. For example, 
travel to rural or heavily forested areas in tropical countries 
may increase the risk that a traveler will come in contact 
with mosquito vectors known to transmit certain diseases 
(eg, yellow fever, Japanese encephalitis), particularly dur-
ing peak seasons coinciding with heavy rainfall. In contrast, 
travel limited to urban areas in developed countries may 
present few, if any, risks of exposure to mosquitoes.
If pretravel vaccination is advisable, the physician’s 
clinical assessment, based on the mechanism and degree of 
the traveler’s immunosuppression (Table 2),5 should guide 
restrictions on what types of vaccines can be administered, 
what level of response to expect, and whether revaccination 
will be necessary. Inactivated vaccines are considered safe in 
all immunocompromised patients but may not reliably elicit 
protective responses. Live vaccines (eg, yellow fever) carry 
a significant risk of vaccine-related infection in patients with 
severe immunosuppression and are therefore discouraged in 
this subset of travelers. Vaccinations should be administered 
early on to achieve sufficient immunity before travel and 
allow time to receive boosters when indicated as part of 
a series. Serological testing for immunity conferred from 
these vaccinations, as well as from vaccinations received 
in the past, is warranted to determine if additional boost-
ers are needed. Antibody response to vaccination is often 
muted in immunocompromised patients, as evidenced by 
lower protective titers maintained over shorter durations. 
Borderline protective titers may not be fully indicative of 
the level of protection conferred by vaccination because 
cellular immunity also plays an important role in prevent-
ing disease.6
If the individual is not a candidate for immunization, 
vaccines are unlikely to be protective, or the risk of disease 
acquisition is high, the patient may be advised to alter his or 
her travel itinerary. This is particularly true with live vac-
cines and their potential for adverse events, most notably 
with vaccination against yellow fever preceding travel to 
endemic areas in South America or Africa. Travel to high-
risk destinations should be delayed for at least 1 year in 
several situations. These include patients with a history of 
transplantation or those on high doses of immune-modulating 
Table 1 items to discuss during the travel visit with an immuno­
compromised traveler
Checklist for pretravel advice
1. Assess the traveler’s health
immunosuppressive medications
Time of transplant and other pertinent history (ie, graft­versus­host 
disease, etc)
immunization history and related allergies
Other pertinent medical history
2. Assess the risk of disease exposure
Countries of travel, including transit countries
Location of travel (urban versus rural)
Peak disease transmission
Accommodations
Food sources (ie, street carts)
Activities (ie, safaris and jungle tours)
Determine entry requirements for yellow fever­endemic country
3. Administer vaccines and relevant counseling
Travel vaccines (as applicable): polio booster (inactivated), typhoid 
(inactivated), tetanus booster (along with diphtheria and pertussis), 
hepatitis A, yellow fever (as applicable), rabies, Japanese encephalitis, 
hepatitis B
Routine vaccines (as applicable): measles, mumps, rubella (MMR)  
(in certain situations), influenza (inactivated), tetanus booster  
(along with diphtheria and pertussis), hepatitis B, pneumococcal
Counsel regarding travel companions’ vaccinations
Counsel regarding vaccine efficacy and duration
Administer immunoglobulin for certain diseases in certain scenarios
4. Administer medical prophylaxis
Traveler’s diarrhea
Malaria
Leptospirosis (in certain situations)
5. Medical care
Create medication and medical history list
Create medical letter of necessity for medications to keep in hand luggage
Have medical evacuation insurance
Define hospitals to seek medical care
Provide yellow fever vaccine waiver document (as applicable)
Change dosing of immunosuppressive agents if possible
6. Counseling
Food and water safety
injury prevention (ie, motor vehicle safety, etc)
Mosquito, insect, and animal avoidance
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medications. In addition, immune-related diseases should 
stabilize or be brought under good control prior to travel. 
Immunizations should be given prior to the initiation of 
any immunosuppressive therapy if possible. Alternatively, 
immunizations can be deferred. The timing of deferred vac-
cinations depends on the nature of the immunosuppression. 
Specifically, vaccines should be deferred until 1) 1 month 
after discontinuation of tumor necrosis factor inhibitors or 
corticosteroids, 2) several months to 1 year after discontinu-
ation of monoclonal antibody therapy (eg, rituximab), or 3) 
once other immunosuppressive drugs can be administered at 
lower doses or discontinued altogether.6 Immune responses 
and the duration of immunity will vary with different vac-
cines in the immunocompromised population.7–9 In regions 
with ongoing outbreaks or emerging infectious diseases (eg, 
viral hemorrhagic fever), travel is strongly discouraged.
Chemoprophylaxis may be recommended primarily in 
the context of traveling to regions where malaria is endemic. 
Selection of an appropriate prophylactic regimen should 
take into account the potential for drug interactions with a 
traveler’s existing medications, including immunosuppres-
sive agents and antivirals.
Travel vaccines
As stated earlier, the safety and efficacy of individual vac-
cinations depends on the timing and degree of immuno-
suppression. The following section describes precautions, 
indications, and advice for specific vaccinations as they relate 
to the immunocompromised traveler.
Yellow fever
Yellow fever (YF) is caused by a flavivirus that is transmitted 
by the Aedes aegypti mosquito and no treatment exists for 
this disease (Figure 1A and B). Infections occur throughout 
South America and sub-Saharan Africa. The case fatality 
of severe YF with hepatorenal disease ranges from 20% to 
Table 2 Categories of immunocompromise based on type of immune suppression
Category Description
1. Diseases without immune compromise Hiv with CD4 $500/mm3
Malignancy with chemotherapy $3 months ago and in remission
SOT or BMT $2 years with no immunosuppressive treatment and no GvHD
Corticosteroids #20 mg of prednisone or equivalent for #2 weeks; inhaled or 
topical corticosteroid use
Autoimmune disease without treatment
Multiple sclerosis with no exacerbations and no treatment
2. Diseases and therapies with limited immune compromise Hiv with CD4 200–500/mm3
Complement deficiencies




Multiple sclerosis with exacerbation but not on treatment
Nutritional deficiencies
3. Diseases and therapies with severe immune compromise Hiv with CD4 #200/mm3 (or CD4 percentage ,15)
BMT #2 years or on immunosuppressive treatment or with GvHD
SOT #1 year or on immunosuppressive treatment or with GvHD
Treatment for rejection after SOT





Prednisone (or corticosteroid equivalent) $2 mg/kg of body weight per day 
or $20 mg of daily prednisone or equivalent in those $10 kg for a duration of 
$2 weeks
Medications: alkylating agents, antimetabolites, chemotherapeutics, 
immunomodulators, or TNF blockers
Thymus disorder (in the case of yellow fever vaccination)
Note: Copyright © 2014. Adapted from Kotton CN, Freedman DO. Advising Travelers With Specific Needs:Immunocompromised Traveler. Chapter 8: The Yellow Book; 2014. 
Available from: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-8-advising-travelers-with-specific-needs/immunocompromised-travelers.48
Abbreviations: BMT, bone marrow transplant; GVHD, graft-versus-host disease; HIV, human immunodeficiency virus; SOT, solid organ transplant; TNF, tumor necrosis 
factor.





50% and the estimated number of deaths is 30,000 per year. 
Clinical presentations can include an asymptomatic illness 
or a febrile illness with headaches, myalgias, and jaundice. 
A hemorrhagic presentation can occur with multiorgan 
failure. Between 1997 and 2009, nine cases were reported 
in unvaccinated travelers; eight persons died. One case of 
infection has been documented in a vaccinated traveler.10 
A traveler’s risk for YF is based on the season of travel, level 
of immune competence, travel location, and anticipated travel 
activities (eg, jungle or safari tours increase risk). Despite 
the severity of the infection, the risk for travelers to most 
tourist destinations remains quite low. The calculated risk 
of acquiring YF during a 2-week trip to West Africa for an 
unvaccinated traveler is 50 cases per 100,000 population.10
The 17D YF vaccine is a live vaccine. In immunocompetent 
individuals, neutralizing antibodies can be detected 10 days 
after vaccination. After 28 days, nearly 99% of vaccinated 
individuals demonstrate YF-neutralizing antibodies. Duration 
of protection is currently thought to be .10 years. Failure to 
create antibodies has been shown in those with malnutrition 
and HIV infection. The vaccine is contraindicated in travelers 
with severe immune deficits (Table 2) due to the risk for life-
threatening adverse reactions, including vaccine-associated 
viscerotropic disease (YEL-AVD) and vaccine-associated 
neurologic disease (YEL-AND). According to the Vaccine 
Adverse Event Reporting System, 43 adverse events occur 
per 100,000 doses distributed. The majority are nonserious 
events, including fever and pain at the injection site. From 
2000 to 2006, 4.7 serious adverse events have occurred per 
100,000 doses, which have been classified into YEL-AND, 
YEL-AVD, and anaphylaxis or hypersensitivity.5,10
YEL-AND is more common in children. In adults, 
YEL-AND manifests as Guillain-Barré syndrome, menin-
goencephalitis (neurotropic disease), acute disseminated 
encephalomyelitis, and a bulbar palsy. YEL-AND is rarely 
fatal. The reporting rate of YEL-AND is 0.4–0.8 cases per 
100,000 doses distributed and, among persons $60 years, 
the rate is 1.6 cases per 100,000 doses.10
A total of 57 cases of YEL-AVD from 14 countries has 
been reported since 2010. YEL-AVD is a disseminated pro-
cess that presents with fever and multiorgan failure. Cases 
have primarily been reported with first-time vaccination and 
not with booster vaccinations. The reporting rate for YEL-
AVD is 0.3–0.4 cases per 100,000 doses distributed, with 
higher rates reported among persons $60 years. Thymic 
diseases that cause immune deficiencies (ie, myasthenia 
Figure 1 (Continued)
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Figure 1 CDC maps of regions of Africa (A) and South America (B) at risk for yellow fever transmission.49
Notes: Yellow­shaded regions represent areas where vaccination is recommended, while gray areas have minimal risk of yellow fever transmission. *Not recommended 
unless individual practice patterns suggest higher risk. The CDC plans to publish updated maps in 2015, and the most current recommendations can be found online at www.
cdc.gov. Copyright © 2014. Adapted from Gershman MD, Staples Je. Infectious Diseases Related to Travel:Yellow Fever. Chapter 3: Yellow Book; 2014. Available from: http://
wwwnc.cdc.gov/travel/yellowbook/2014/chapter­3­infectious­diseasesrelated­to­travel/yellow­fever.49
Abbreviation: CDC, Centers for Disease Control and Prevention.





gravis or thymoma) have been associated with YEL-AVD as 
four of the first 23 (17%) cases of YEL-AVD were associated 
with thymic disorders. Autoimmune diseases are thought to 
be a risk factor for YEL-AVD, and occurrences have been 
reported in patients with systemic lupus erythematosus, 
Addison’s disease, and Crohn’s disease. It is unclear if this 
is due to immunosuppressive treatment for the disease or the 
disease pathophysiology itself.10,11 These patients should be 
advised against travel to YF-endemic regions.
The Advisory Committee on Immunization Practices 
recommends vaccination for HIV-infected travelers with 
CD4 .200/mm3 as a “precaution” if travel is unavoidable. 
“Precaution” means that vaccine-related adverse events 
are higher in this population versus the general population 
and that the travel itinerary should be modified to avoid 
disease exposure. Duration of protection in these individuals 
is ,10 years, unlike in healthy hosts, and the immunologic 
response is related to HIV viral load (versus CD4 count).12,13
Immunocompromised persons may not develop a 
response to the vaccine. Serologic testing should be obtained 
1 month postvaccination. Serologic testing information can 
be obtained from either the state health department or the 
CDC. Conditions in which there is no contraindication or 
precaution for YF vaccination include presence of renal or 
liver diseases, asplenia, or diabetes mellitus.5,14 Those on 
corticosteroids can be given the vaccine under certain cir-
cumstances, including if they have been on corticosteroids 
for ,2 weeks and are on a daily dose of prednisone (or 
equivalent) #2 mg/kg or #20 mg, on physiologic doses, 
on alternate-day dosing, or are using topical formulations 
(Table 1).10 Immunization of SOT recipients is best pursued 
prior to transplant, as with all live vaccines.2
In situations wherein YF vaccine is required for essential 
travel but is contraindicated, the traveler should be given a 
vaccine waiver as well as information on the symptoms of YF 
and mosquito avoidance. Travel should be deferred to low-
risk seasons. The traveler should check with the respective 
country embassy or travel agent to determine if the waiver 
will be accepted.
Typhoid
Salmonella enterica serovar typhi is a gram-negative bac-
terium that causes fever, diarrhea, and abdominal pain. In 
severe cases, disease may result in sepsis, thrombocytopenia, 
or intestinal perforation. Transmission is via a fecal–oral 
route and most travelers to endemic regions should receive 
vaccination. It is the most common vaccine-preventable 
disease acquired during travel.15
Currently, there are two available vaccines, an oral live-
attenuated Ty21a vaccine and a parenteral Vi polysaccha-
ride capsule vaccine. Both are directed against Salmonella 
typhi and effectiveness varies between 50% and 80%.16 
Additionally, Salmonella paratyphi A and B cause similar 
clinical symptoms and the live vaccine provides some cross-
protection against these strains.17
The live, oral vaccine is given as an enteric-coated cap-
sule for four doses over 1 week and should be given at least 
1 week prior to travel. It is licensed for adults and children 
aged 6 years or older. Protection lasts about 5–7 years and a 
booster is recommended every 5 years in persons traveling 
to endemic regions.18 Adverse reactions are uncommon but 
include fever and headache. Less common reactions include 
nausea, vomiting, and urticarial rash.19 However, as with all 
live vaccines, it is contraindicated in immunocompromised 
individuals.
In contrast, the Vi polysaccharide vaccine comprises a 
single intramuscular injection. It is indicated for adults and 
children aged 2 years or older, and seroconversion is achieved 
in .85% of immunocompetent adults. Vaccine efficacy lasts 
2–3 years and booster vaccination is recommended every 
2 years.18,20 Adverse reactions also include redness or pain at 
the injection site, muscle aches, and fevers. Coadministration 
of other intramuscular vaccines may produce increased red-
ness at the Vi injection site. The only contraindication to its 
administration is a previous history of severe skin reaction 
associated with the Vi vaccine.21
There are very limited data on the effectiveness of the 
Vi vaccine in the immunocompromised individual, but 
it should be administered to those traveling to endemic 
regions. HIV patients with CD4 counts ,200/mm3 will have 
decreased antibody responses compared to those with CD4 
counts .200/mm3.22 In view of such limited data for the 
immunocompromised host, even after vaccination, it is of 
paramount importance that proper food and water hygiene 
measures be employed for disease prevention.
Hepatitis A
The hepatitis A virus is transmitted via the fecal–oral route 
and can lead to fulminant liver failure in the immunocom-
promised host. It is the second most common vaccine- 
preventable disease acquired during travel.15 Estimated 
risk has been calculated among unvaccinated individuals to 
be 4–30 cases per 100,000 months of stay in a developing 
country.23 The injectable vaccination requires two doses, 
administered 6–12 months apart, in SOT recipients who are 
a year or more post-transplant. The immunological response 
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in SOT recipients is suboptimal and has a shorter duration 
compared to that in immunocompetent hosts. In 39 liver 
and 39 kidney transplants, seroconversion following two 
doses of the hepatitis A vaccine occurred in 72% and 97%, 
respectively, versus 100% in healthy controls. After 2 years, 
immunity persisted in 26%–59% of transplant recipients ver-
sus 100% of healthy controls.24 Among rheumatoid arthritis 
patients on methotrexate and tumor necrosis factor inhibitors, 
vaccination with one dose of hepatitis A vaccine resulted 
in poor seroconversion rates.2,6 Thus, it is recommended 
that the immunocompromised traveler be vaccinated with 
two doses administered 6 months apart prior to departure. 
If time permits, then check for seroconversion 4 weeks 
prior to departure and, if the patient is seronegative, admin-
ister hepatitis A gamma globulin. If time does not permit 
adequate vaccination (eg, patient presents 2 weeks prior to 
travel), consider administering gamma globulin alone or 
in combination with hepatitis A vaccine.2,6 Immunocom-
promised travelers who receive routine intravenous immu-
noglobulin do not require vaccination against hepatitis A 
or measles.5
Japanese encephalitis
Japanese encephalitis (JE) is caused by a flavivirus, result-
ing in meningitis, encephalitis, seizures, paralysis, and other 
neurologic disorders. It is transmitted by mosquitoes and is 
endemic in Southeast Asia, including several popular travel 
destinations in India and Thailand. In 2004, over 5.5 million 
travelers from the US visited JE-endemic countries. Case 
fatality is 20%–30% and neurologic sequelae exist in 
30%–50% of survivors.25 There is no treatment for JE apart 
from supportive care. Risk for disease acquisition depends 
on location of travel, activities during travel, and duration 
of travel. It is estimated that travel for prolonged periods in 
endemic countries puts one at similar risk for JE as that of 
the resident population (5–50 cases per 100,000 children per 
year). Outdoor activities in rural areas put travelers at greater 
risk, while travel limited to urban areas presents minimal 
risk for JE.25 There is only one inactivated vaccine available 
in the US (Ixiaro) and it involves the administration of two 
intramuscular doses 28 days apart. Each dose costs nearly 
$300–$400 and, in terms of cost-effectiveness, understand-
ing the detailed itinerary is important to determine JE risk 
and the need for vaccination. Vaccination is recommended 
for long-term travelers (.30 days) to endemic areas and 
short-term travelers during peak seasons, as well as for those 
traveling to rural areas, those who are likely to engage in 
outdoor activities, and those venturing into a JE-outbreak 
area. The vaccine is not recommended when short-term travel 
is restricted to urban areas or when travel occurs outside of 
JE transmission season.25
Rabies
The rabies virus is transmitted by the bite of an infected 
mammalian host, resulting in fatal encephalitis in almost all 
cases. Canine rabies is enzootic in Asia, Africa, and South 
and Central America, as well as in other places. The risk 
of rabies among travelers in different studies has been esti-
mated at 16–200 per 100,000 travelers.5 The rabies vaccine 
consists of an injectable inactivated virus. It is recommended 
for those who plan on long-term (.30 days) travel, have fre-
quent animal exposures, and travel to areas where medical 
care is not easily accessible. Immunologic response may be 
inadequate in some instances, and there are few data related 
to this vaccine in immunocompromised individuals. Even 
if adequate vaccination is provided, exposed travelers must 
present to health care providers for additional postexposure 
prophylaxis. Vaccination extends the window of opportunity 
in which one can delay postexposure prophylaxis but does 
not prevent infection. Patients exposed to the rabies virus 
should strongly consider medical evacuation.26
Bacille Calmette­Guerin vaccine
Bacille Calmette-Guerin (BCG) is a live vaccine that can 
prevent active and severe tuberculosis but is contraindicated 
in the immunocompromised host. Vaccination can cause 
disseminated infection, termed BCGosis. The role for this 
vaccine even in healthy travelers remains controversial. 
Alternatively, pre- and posttravel detection of tuberculosis 
infection can be obtained through an interferon-gamma 
release assay, which may be superior to the purified protein 
derivative skin test, as the latter may be falsely negative in 
the immunocompromised patient.5,27
Routine vaccines
Routine vaccines should be recent for immunocompromised 
travelers. They are discussed separately in the following 
subsections.5,14,28
Polio vaccine
Poliovirus causes myelitis with flaccid paralysis, and it has 
gained resurgence in selected Asian and African countries 
due to conflict; it is transmitted via a fecal–oral route. 
Two vaccine forms exist, the live oral and the injectable 
inactivated. The inactivated polio vaccine is recommended 
for immunocompromised individuals who are traveling to 





regions with polio outbreaks, in addition to their routine 
childhood series of vaccines. The live oral vaccine should 
not be given to household contacts of the immunosup-
pressed. The oral vaccine is no longer available in the US 
or Canada. Routine vaccination involves a childhood series 
and one booster; another booster should be given if vac-
cination was .10 years ago and travel involves going to 
a polio outbreak area or one with known circulating virus. 
Immunity is thought to last 5–10 years postvaccination in 
prior transplant recipients.29
Meningococcal vaccine
The meningococcal vaccine is recommended for those 
traveling to high-risk settings such as the “meningitis belt” 
in sub-Saharan Africa during the winter (dry) months of 
December–June and for those traveling to Saudi Arabia for 
the Muslim pilgrimage of Hajj/Umrah. Vaccination is recom-
mended with the quadrivalent polysaccharide (Menactra™). 
Immunocompromised travelers, especially those with pri-
mary complement deficiencies or asplenia, should be vac-
cinated every 5 years.14,30
Tetanus/diphtheria/pertussis vaccine
The acellular tetanus or Tdap vaccines can be given to 
those who have not received a booster within 10 years. 
Tetanus is common in most low-resource settings and, albeit 
rare among travelers, vaccination should be considered 
essential prior to travel. Diphtheria and pertussis should be 
considered while traveling to regions of the world where 
it is endemic and vaccination should be scheduled every 
10 years. Seroprotection may wane more rapidly in SOT 
recipients, and diphtheria antibody titers should be assessed 
to determine the need for vaccination if they are below the 
protective titers.2
Hepatitis B vaccine
Hepatitis B vaccination is essential when traveling to low-
resource settings in case medical care is sought. Hepatitis 
B can be acquired through blood transfusions and other 
iatrogenic scenarios or through sexual contact. Factors affect-
ing standard hepatitis B immune response include recent 
transplant and prior graft-versus-host disease.28 A three-dose 
series can be given and serologic testing should be performed 
to detect a level $10 mIU (international units)/mL of anti-
hepatitis B surface antibody. If levels are not adequate, then 
a second three-dose series can be given using the standard 
or high (40 μg) vaccine dose.14
Influenza vaccine
Inactivated influenza vaccines should be administered annu-
ally unless there is profound immunosuppression, such as 
active treatment for transplant rejection or recent transplant 
prior to vaccination. In tropical regions, influenza occurs 
round the year, and so vaccination prior to departure for 
those unvaccinated within the year is prudent. Live attenuated 
influenza vaccines are contraindicated in these situations.
Pneumococcus vaccine
Immunization with both pneumococcal 13-valent conjugate 
(PCV13) and pneumococcal polysaccharide (PPVS23) 
vaccine is recommended for adults $65 years, followed 
by revaccination with PPV23 every 5 years. Vaccination 
with PCV13 is recommended in those ,65 years who are 
immunocompromised or have asplenia, with revaccination 
at 5-year intervals with PCV13.14,31,32
Measles, mumps, rubella vaccine
Measles is a viral disease spread via large respiratory drop-
lets. While the US is disease free, outbreaks have occurred 
in Europe and in developing countries.33 Measles, mumps, 
rubella (MMR) is a live virus vaccination and is contrain-
dicated in persons with primary and secondary causes of 
humoral or cellular immune deficiencies, including those 
with HIV infection #200/mm3 (or T cell percentage ,15). 
Measles inclusion body encephalitis, pneumonitis, and death 
have been reported with vaccination in immunocompromised 
individuals.34 Serologic testing should be sought among SOT 
recipients prior to travel to endemic regions. For pre- and 
posttravel exposure, short-term immunoglobulin therapy 
can be given.5,6
Risk of vector-borne diseases 
and mosquito-related precautions
Vector-borne diseases include diseases transmitted by a 
range of insects, including mosquitoes, sand flies, ticks, 
and triatomes. Vaccinations or prophylactic medications 
are not available for many of these diseases, which are 
briefly discussed in the following subsections. Immuno-
compromised travelers are not necessarily at increased 
risk for infection from vector-borne diseases, but should 
they become ill, disease can be more severe.2,35 This 
remains especially true for malaria, leishmaniasis, and 
Chagas disease, while limited data exist for other infec-
tions such as dengue fever and chikungunya.36–39 Both 
leishmaniasis and Chagas disease can disseminate in 
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immunocompromised patients, particularly HIV-affected 
and transplant patients.36,37 No vaccines or prophylaxis is 
available for either of these illnesses, and disseminated 
disease is refractory to treatment.
The dengue virus and the chikungunya virus (CHKV) 
are transmitted by mosquitoes. Dengue infections are quite 
common, accounting for roughly 10% of systemic febrile 
illnesses in travelers, suggesting that immunocompromised 
travelers are at risk.40 Any increase in disease severity is 
poorly understood at this time. CHKV has emerged in recent 
years, first in the Reunion Islands, spreading to Italy and, 
most recently, to the Caribbean and the US.41 As in den-
gue, limited information regarding the severity of CHKV 
in immunocompromised patients is available. Currently, 
no vaccines are available for either of the viruses, and 
supportive therapy is the only treatment option. For all of 
these illnesses, if the risk of infection is deemed high, travel 
should be delayed until disease incidence is decreased or 
immunosuppression is reversed; otherwise, travel should 
be avoided altogether.
Patients should strictly adhere to vector avoidance mea-
sures if travel to endemic areas is necessary.5 This includes 
avoidance of mosquitos, especially during dusk and dawn 
when mosquitoes that transmit malaria are most likely 
to bite. Patients should wear long pants and shirtsleeves. 
A minimum of 20% diethyltoluamide should be applied. If 
indicated, patients should sleep under bed nets, especially 
in rural settings.
Malaria and chemoprophylaxis
Malaria is a major concern for travelers to endemic settings 
and the commonest cause of febrile illness in travelers.40 
Severe illness arises in immunocompetent but previously 
nonexposed adults and pregnant women. Conflicting evi-
dence exists on whether or not HIV progresses in the setting 
of malaria, especially in HIV-positive travelers, but severe 
malaria is more common in HIV-positive patients.38 Likewise, 
limited data are available for other forms of immunosuppres-
sion, but concern for severe disease persists.5 All travelers to 
malaria-endemic regions should receive chemoprophylaxis 
based on CDC guidelines.42 For immunosuppressed patients, 
care must be taken to evaluate for drug interactions.2 Meflo-
quine can increase the concentration of calcineurin inhibi-
tors, but it is safe in renal failure. Atovaquone/proguanil is 
generally considered safe in most circumstances, but its use 
may be limited by cost. Doxycycline may be useful but can 
reduce mycophenolate levels.
Traveler’s diarrhea and food safety
Up to 50% of all travelers will experience a gastrointestinal 
illness.5,43 The most common cause is enterotoxigenic 
Escherichia coli (ETEC). While most food-borne illness is 
self-limited, immunocompromised travelers remain at risk 
for severe infection from bacteria and parasites.5 For ETEC, 
the rapid onset of voluminous diarrhea can induce renal 
failure and subsequent medication toxicities.2 Other bacte-
rial infections of concern include Salmonella spp, Campy-
lobacter spp, and Shigella spp. Prophylactic antibiotics such 
as ciprofloxacin or rifaximin may be useful, especially for 
short-term travel, but carry risks (eg, Clostridium difficile-
associated diarrhea with ciprofloxacin). Breakthrough illness 
does occur and it is imperative that immunocompromised 
travelers take prophylactic antibiotics with them. The choice 
of agent must be balanced with possible drug interactions 
and the location of travel. Fluoroquinolones are frequently 
prescribed but run the risk of QT prolongation or spontaneous 
tendon rupture. Azithromycin is frequently prescribed due to 
high rates of fluoroquinolone resistance in Campylobacter in 
Southeast Asia.43,44 This medication can also prolong the QT 
interval and increase the serum concentrations of calcineurin 
inhibitors.2
Parasitic infections occur in 1%–20% of travelers with 
diarrhea depending on the study and location.2 Cryptospo-
ridia, Giardia, and Cyclospora infections are all self-limited 
in immunocompetent patients but can cause prolonged severe 
diarrhea in immunocompromised patients. Treatments are 
of minimal efficacy, especially for cryptosporidia.45
Patients should maintain good food safety practices to 
avoid infections with these agents as well as avoiding bacte-
rial infections.5 Any food that has not been thoroughly cooked 
should be avoided. Cooked food should be eaten immediately 
and not be allowed to sit, such as in buffet style dining. Under-
cooked shellfish and seafood should also be avoided to pre-
vent infections with viruses (eg, hepatitis E, hepatitis A, and 
norovirus), parasites (eg, anisakiasis, paragonimiasis), and 
bacteria (eg, Vibrio species). Undercooked meat can lead to 
infections with gram-negative organisms, such as Escherichia 
coli 0157 and Campylobacter, and parasites, such as Toxo-
plasma, Taenia solium, Entameoba, and tapeworms. Fresh 
fruits that can be peeled are considered safe. Unpasteurized 
milk products, including soft cheeses, can place travelers at 
risk for gram-negative infections with Listeria and Brucella. 
Foods with raw eggs, including Hollandaise sauce and mayon-
naise, put travelers at risk for Salmonella infection. Bottled 
or boiled drinking water is advised.





Avoidance of other infectious 
diseases
Fungal diseases
Fungi transmitted through respiratory inhalation, such 
as Cryptococcus, Histoplasma, Paracoccidioides, and 
Penicillium, may cause respiratory and/or disseminated 
disease in the immunocompromised host.46 Caving and 
other outdoor activities that place travelers at risk should 
be avoided.
vaccination of close contacts
Close healthy contacts of an immunosuppressed patient who 
have received a live vaccine can shed and transmit virus to 
the immunosuppressed host. In general, these close contacts 
should avoid receiving the live influenza and oral polio vac-
cines. Yellow fever, typhoid, and MMR have been shown to 
be safe in close contacts.
insect­related precaution
Mosquitoes, sand flies, chiggers, and ticks can carry dis-
ease, and an insect repellent containing diethyltoluamide 
is advised. Application several times a day is necessary. 
Clothing to cover the arms, ankles, and legs is recommended 
despite temperature conditions. Ticks can carry rickettsial 
disease, tick-borne encephalitis, Lyme disease, and other 
diseases not previously mentioned.
Diseases from skin exposure
Travelers should avoid walking barefoot or swimming in 
freshwater, which can put them at increased risk for abrasions, 
infections, and parasitic disease. Strongyloides can penetrate 
intact skin and can cause a hyperinfection syndrome, a risk 
that is higher if the traveler is taking corticosteroids. Other 
parasitic infections include hookworm and schistosomasis. 
Leptospirosis, caused by a gram-negative bacterium, can 
result in fever as well as liver and renal failure, and is 
acquired through skin contact with infected rodent urine. 
Evidence supporting prophylaxis against leptospirosis is 
ambiguous; however, the CDC recommends doxycycline 
200 mg weekly starting 1–2 days prior to and during high-
risk exposures (ie, floods, heavy rainfall, and recreational 
water activities).5,47
Sexually transmitted diseases
Travelers need to use barrier precautions when engaging in 
sexual encounters. Recreational drugs and alcohol can create 
scenarios of increased HIV transmission risk in countries 
where prevalence is high.
emerging epidemics
Emerging outbreaks such as the current Ebola epidemic will 
continue to occur. Specific information regarding prevention 
in such unique situations, especially in the setting of immuno-
compromised travelers, is beyond the scope of this article. 
Travelers in general are advised to avoid travel to affected 
regions. Physicians should be aware of ongoing epidemics, 




Several noninfectious disease-related precautions should be 
discussed during the travel consultation, including potential 
drug interactions, altitude sickness, dehydration, heat stroke, 
injury prevention, predeparture planning for medical evacu-
ation, and thromboembolism precautions. Adjustments in 
immunosuppressive medication may be necessary during 
travel. Injury is the leading cause of preventable death in 
the traveler and is often related to motor vehicle accidents. 
Wearing seatbelts and arranging safe in-country transport 
predeparture is important.5 Transplant recipients are at 
increased risk of skin cancer and photosensitivity while being 
on voriconazole.2 Sunscreen lotions offering ultraviolet A 
protection and avoidance measures (eg, wearing a hat) are 
advised.
Immunocompromised travelers should identify health 
care facilities abroad where they may seek care in the event 
of an emergency. A list of facilities can be found on the CDC 
and US Department of State Web sites. Emergency evacua-
tion insurance should be purchased and is usually different 
from routine health care coverage. Travelers should bring 
excess medications in case of travel delays accompanied by 
a letter of necessity. All medications and syringes should 
be carried in hand luggage and stored at the appropriate 
temperature. If medical care is required abroad, consultation 
with transplant, rheumatology, and/or infectious diseases 
specialists is crucial for medical decision making.
Conclusion
More immunocompromised patients are traveling worldwide 
and a dedicated predeparture travel visit to discuss infec-
tious disease prevention and other noninfectious disease 
precautions is strongly recommended. While the list of 
precautions described herein may sound excessive, many 
simple measures can prevent life-threatening complications. 
This review is not meant to discourage travel, but instead 
to encourage safe travel. Clinical assessment and advice 




Travel advice for the immunocompromised traveler
for vaccination begins with defining the mechanisms and 
degree of immunosuppression. Live vaccine formulations, 
which include YF, oral polio, MMR, BCG, and oral typhoid 
vaccines, are generally contraindicated in those with severe 
immunosuppression. Vaccines to be administered are based 
on the patient’s immunosuppression level, region of travel, 
activities during travel, risk of disease exposure, and duration 
of travel. Immunologic response and duration of vaccine-
induced immunity is dependent on the type of vaccine and 
the host’s immune system. Routine vaccines should be 
updated prior to travel. Chemoprophylaxis against malaria, 
mosquito-oriented precautions, and food safety to prevent 
traveler’s diarrhea should be discussed. Consultation with 
an infectious diseases specialist is strongly recommended 
to optimize the pretravel care of all immunocompromised 
travelers. This article addresses the key issues regarding 
the immunocompromised traveler within the limitations in 
providing an exhaustive review of the subject matter.
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